Open in interactive viewer → charts, metric popovers & call review

Lifeway: Record Sales, Negative Free Cash Flow, and a Stock That Already Knows

A 28-quarter growth streak, a plant that can't keep up, and the balance-sheet bill for doubling capacity — the Q3 print is a demand story the tape has stopped paying for
LWAY · Earnings Call · 2026-11-12

Lifeway Foods just posted the best top line in its forty-year history and the market has spent the last four months selling it. Third-quarter net sales hit $67.8 million, the 28th consecutive quarter of year-over-year growth, and through nine months revenue reached $197.7 million — up 25.8% and already 93% of the entire 2025 total of $212.5 million. Fortune put the company at #45 on its list of America's 100 fastest-growing companies. Meanwhile the shares are down roughly 25% over the last ninety trading days and sit about 31% below the July peak of $32.33, and 34% below the September 2025 high of $33.82, on a $316 million market cap.

That gap between the income statement and the tape is the story. Nothing about demand broke. What broke — or rather, what got exposed — is that Lifeway is now a company selling less than it could, at margins far below its own history, while writing very large checks to fix both.

A company on allocation

The freshest thing in this quarter's language is supply, not demand. The company's keyword profile for Q3 is dominated by a cluster it has never leaned on this hard before: capacity challenges, Waukesha plant work, the planned shutdown, and the throughput math of bottles per minute. Prior quarters were about distribution wins, velocity, marketing, and shelf space. This one is about a factory.

“Despite these capacity limitations, we still grew nearly 19% this quarter and we would have grown even more if we had the space and equipment. It is a good problem to have but it is still a problem” — Julie Smolyansky, President and Chief Executive Officer · 2026-11-12

Management was unusually blunt about the shape of it. Asked whether existing customers simply wanted more than Lifeway could ship, the CEO answered: “We are on allocation and the demand is rising in our existing -- all of our existing customers.” — Julie Smolyansky, President and Chief Executive Officer · 2026-11-12 The company also absorbed roughly a week of planned downtime at Waukesha, and noted some orders that slipped from the last days of Q3 into the first weeks of Q4.

The fix is the whole investment case: capacity at Waukesha runs from 200 bottles per minute to more than double, with capacity increases rolling out quarterly beginning in January 2027 and the bulk of the upgrades landing in February.

I don't expect 2027 to be a conversation around capacity. The majority of 2027 will have full capacity. So that should not be an issue.

Julie Smolyansky, President and Chief Executive Officer · 2026-11-12

That is a credible, datable claim — and it is the single line the market will grade this company against next year.

The margin bill for that growth

Volume growth at any price is not growth. Q3 gross margin fell to 18%, versus roughly 29% a year earlier, and operating income was about $0.6 million against $3.5 million of net income a year ago — this quarter's net income was $0.3 million, or $0.02 per share, down from $0.23. The culprits are named and boring: Milk prices rose approximately 26% sequentially in Q2 and barely eased in Q3, and higher oil fed packaging and freight. Management guided Q4 gross margin to land somewhere between the Q2 and Q3 levels, with average milk cost higher in Q4 than Q3. No relief this calendar year.

Gross margin v=19.5% in fiscal Q2 2026, down 9.1pp year over year

The offset is pricing. Lifeway is taking increases across the portfolio on a rolling basis through year-end and into Q1 2027 — and notably, this is the first broad move since 2022: “the last time we took price was in 2022.” — Julie Smolyansky, President and Chief Executive Officer · 2026-11-12 Layer that on the Waukesha efficiencies and the company's stated ambition is to get back to “our historic margins of 25% plus” — Julie Smolyansky, President and Chief Executive Officer · 2026-11-12. The one place leverage is already visible is overhead: SG&A fell to 16.2% of net sales from 19.6%.

The balance sheet is financing the unlock

Here is the tension the cheerleading obscures. Growing into a plant is expensive, and Lifeway is paying for it out of its own pocket at exactly the moment its gross profit is shrinking.

Free cash flow (less SBC): -$9M in fiscal Q2 2026, -664% year over year

Capital expenditure ran $8 million in the quarter, up more than 400% year over year, and the ten-year series shows a step-change in the last three quarters. The consequence is visible in net cash, which has swung from a $21 million surplus in 2024Q3 to a $15 million deficit.

Capex of $8M against $67M of quarterly revenue

Worth flagging: the company also repurchased $5 million of stock in the June quarter while free cash flow was deeply negative and the plant build was in flight. Aggressive capital allocation for a $316 million company funding its own capacity expansion.

Riding a wave it did not create

The demand tailwind is real and the company is honest that it is a rider, not the weather system. Gut health, protein density and GLP 1 use are the framing, and the broader tape agrees — GLP-1 exposure shows up among the market's ninety-day advancers, with GLP 1 growth in the winning column across drug and consumer names. Lifeway's pitch is that kefir sits at the intersection of satiation, digestive health and real food, and that no one has spent longer building trust there.

But note the contrast: the GLP-1 complex has been an advancing tape over the last ninety days while Lifeway has de-rated. The company is levered to the theme and the theme is working; the equity is not being paid for it because the bottleneck is internal — capacity and margin — not end demand. That is the whole bull case in a sentence: the demand is borrowed against 2027.

The portfolio build-out is genuine but subscale: Farmer Cheese now in select Target stores with a new organic version at Erewhon and Sprouts, Muscle Mates at Kroger and Wegmans, Kefir Butter at Meijer, and frozen kefir back in soft-serve machines through foodservice, a category Lifeway pioneered in 2008. These are new consumers land-grabs, but they will only matter in the units that Waukesha can produce.

The honest read: this is a category leader with a demand queue, a credible one-year capacity unlock, a pricing action with retailer support, and a stock that has already discounted a messy trough. The risk is not demand — it is that the 25%-plus margin promise slips if milk stays elevated, and that 2027's volume growth lands closer to 2026's throttled rate than the rhetoric implies. Management declined to promise the step-up: “I can't speak -- I don't have a total crystal ball but we do believe that we can pull certain levers to push more demand when we know that we have more capacity.” — Julie Smolyansky, President and Chief Executive Officer · 2026-11-12 Watch January and February shipments, price realization at retail, and the milk curve. The record quarters are the easy part now.